<DOC>
	<DOCNO>NCT00335465</DOCNO>
	<brief_summary>The primary objective present study ass change myocardial glucose uptake ( MGU ) clamp study use positron emission tomography ( PET ) scan patient type 2 diabetes idiopathic leave ventricular dysfunction ( LVD ) . The secondary objective study : assessment change myocardial microcirculation rest adenosine stimulation use PET ; assessment change myocardial structure function evaluate magnetic resonance imaging ( MRI ) ; assessment glycaemic control measurement HbA1c , fast blood glucose insulin level ; assessment safety ( adverse event profile , laboratory data ) .</brief_summary>
	<brief_title>Lantus Effect Myocardial Glucose Metabolism T2</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>LV systolic dysfunction ( 2DEcho LVEF &lt; 50 % ) without LV dilation ( 2DEcho LV EDD &gt; 56 mm ) leave ventricular enddiastolic diameter ( LVEDD ) &gt; 55mm without LV dysfunction angiographically normal coronary artery ( &lt; 50 % vessel narrowing ) ; newly diagnose type 2 diabetes ; previously diagnose : OAD treat type 2 diabetic patient able take part study onemonth washout period insulin treat type 2 diabetic patient able take part study one week washout period . evidence congenital valvular cardiac disease , hypertrophic cardiomyopathy , overt heart failure ( NYHA class IIIIV ) ; moderate severe hypertension ( diastolic aortic pressure &gt; 100 mmHg ) ; hypotension ( systolic aortic pressure &lt; 100 mmHg ) ; nephropathy ( serum creatinine &gt; 3 mg/dL ) ; systemic and/or infective disease ; severe dyslipidemia ; peripheral vasculopathy ; necessity vasoactive medical treatment last 48 hour ; atrial fibrillation ; Refusal impossibility give write informed consent ; patient diagnose type 1 insulin dependent diabetes ; clinically relevant cardiovascular , hepatic , endocrine , major systemic disease make implementation protocol interpretation study result difficult ; patient medical history positive cerebrovascular accident , include Transient Ischaemic Attack ( TIA ) ; woman lactate , pregnant , plan become pregnant study ; history hypersensitivity investigational product drug similar chemical structure ; likelihood require treatment study period drug permit clinical study protocol ; treatment investigational product last 30 day 5 halflives ( whichever longer ) study entry ; current use investigational agent participation investigational study study period ; history drug alcohol abuse ; impair hepatic function , show Alamine AminoTransferase ( ALT ) &gt; 2,5 time upper limit normal laboratory range ; mental condition make subject unable understand nature , scope , possible consequence study ; patient unable understand dose direction ; subject unlikely comply protocol , e.g. , uncooperative attitude , inability return followup visit , unlikelihood complete study procedure ; receipt experimental drug use experimental device within 30 day prior study entry ; previous enrollment present study . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>